KFSHRC Detects 276 Fetal Genetic Disorders Through Prenatal Care Saving SAR 360 Million Annually
RIYADH, Saudi Arabia, Feb. 10, 2025 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital & Research Centre (KFSHRC) is enhancing prenatal...
Month: February 2025
Avid Bioservices Launches New Company Website Designed to Boost Company Brand Awareness and Enhance the Visitor Experience
TUSTIN, Calif., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ: CDMO), a dedicated biologics contract development and manufacturing organization...
Boehringer’s nerandomilast meets primary endpoint in Phase III study FIBRONEER™-ILD, in progressive pulmonary fibrosis
Illustrative photo Boehringer Ingelheim Topline data from FIBRONEER™-ILD show that the investigational compound nerandomilast met its primary endpoint, which was...
IMUNON Appoints Douglas V. Faller, M.D., Ph.D., as Chief Medical Officer
Dr. Faller joins IMUNON with more than 30 years of industry, academic and laboratory experience, with specialized expertise in oncology...
Grace Therapeutics Announces Private Placement Financing of up to $30 Million
Financing led by Nantahala Capital and ADAR1 Partners, LP with participation from new and existing healthcare-focused institutional investors $15 million...
Ashvattha Presents Positive Phase 2 Data for Subcutaneous Migaldendranib at Angiogenesis 2025 Conference
Multiple subcutaneous doses safe and well-tolerated >69% reduction in anti-VEGF intravitreal (IVT) treatment burden in study eyes >67% reduction in...
Grace Therapeutics Announces Results From Pivotal Phase 3 STRIVE-ON Safety Trial of GTx-104 in aSAH
Trial Met the Primary Endpoint and Provides Evidence of GTx-104 Clinical Benefit Compared to Orally Administered Nimodipine New Drug Application...
Jasper Therapeutics Announces Briquilimab Presentations at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting
REDWOOD CITY, Calif., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company...
Mustang Bio Announces Closing of $8 Million Public Offering
WORCESTER, Mass., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical...
Qu Biologics’ Immunomodulator Clears Senescence
BURNABY, British Columbia, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs),...
Catheter Precision Inc. Engages PCG Advisory to Broaden Investor Relations Strategy
BRIDGEWATER, N.J., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Catheter Precision Inc. (NYSE American: VTAK) (“Catheter Precision” or the “Company”), a...
Microbot Medical Announces $13 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
BRAINTREE, Mass., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announced that it has entered into...
Tempest Granted Fast Track Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma
Fast Track Designation highlights potential of amezalpat to address unmet need for patients with HCC Amezalpat builds...
Ocean Biomedical Announces Breakthrough Findings in EGFR-Mutant Lung Cancer and Plans for FDA Alignment on Next-Stage Development
Company Poised to Enter Booming Bispecific Antibody Market Amid Growing Pharma Interest Providence, RI, Feb. 10, 2025 (GLOBE NEWSWIRE) --...
New Clinical Trial Data Highlights RAD 101 (18F-Pivalate) Successfully Detects Brain Metastases
Successful detection of brain metastases using RAD 101 (18F-Pivalate) in a novel multiparametric imaging methodology (PET-mpMRI) study across 22 patients.All...
Palvella Therapeutics to Expand Phase 3 SELVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations to Include the Younger Pediatric Population, Children 3 to 5 Years Old
Expansion reflects Palvella's commitment to serving all patients affected by microcystic lymphatic malformations (microcystic LMs) Company remains on track to report...
Medera’s Novoheart Expands Human Cardiac Research with CTScreen™ Installation at University Medical Center, Utrecht
Cutting-Edge Cardiac Research: Novoheart’s CTScreen™ system has been installed at UMC Utrecht, equipping Regenerative Medicine Center with advanced high-throughput tools...
Predictive Oncology Partners with Switzerland-Based Tecan Group Ltd. to Expand High-Throughput Drug Screening to Include Human Tumor Spheroids Using Automated Imaging and 3D Analysis
Study used Predictive Oncology’s vast biobank of cryopreserved live cell tumor specimens for the production and testing of primary patient...
Recludix Pharma to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
SAN DIEGO, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Recludix Pharma, a leader in the discovery of inhibitors of challenging targets...
Alterity Therapeutics Raises A$40.0 million in Placement
– Funds to be used primarily to advance development of ATH434 in Parkinsonian Disorders – – Capital raising was strongly...